InvestorsHub Logo
Followers 167
Posts 35856
Boards Moderated 3
Alias Born 10/20/2019

Re: None

Thursday, 09/29/2022 3:02:11 PM

Thursday, September 29, 2022 3:02:11 PM

Post# of 150
“The Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
- Guido Baechler, Chief Executive Officer of Mainz Biomed, $MYNZ
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYNZ News